Your browser is no longer supported. Please, upgrade your browser.
Settings
SYRS Syros Pharmaceuticals, Inc. daily Stock Chart
SYRS [NASD]
Syros Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own1.60% Shs Outstand25.83M Perf Week-30.25%
Market Cap231.95M Forward P/E- EPS next Y-2.86 Insider Trans- Shs Float21.30M Perf Month-22.39%
Income-49.70M PEG- EPS next Q-0.55 Inst Own76.10% Short Float5.51% Perf Quarter-44.19%
Sales1.40M P/S165.68 EPS this Y-165.30% Inst Trans-1.30% Short Ratio3.64 Perf Half Y-48.92%
Book/sh2.99 P/B3.00 EPS next Y-36.20% ROA-55.60% Target Price26.40 Perf Year-39.49%
Cash/sh3.17 P/C2.83 EPS next 5Y- ROE-62.00% 52W Range6.30 - 24.38 Perf YTD-26.15%
Dividend- P/FCF- EPS past 5Y- ROI-59.30% 52W High-62.71% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low44.29% ATR1.40
Employees55 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)33.71 Volatility21.36% 11.42%
OptionableYes Debt/Eq0.00 EPS Q/Q18.90% Profit Margin- Rel Volume1.19 Prev Close8.98
ShortableYes LT Debt/Eq0.00 EarningsNov 13 BMO Payout- Avg Volume322.27K Price9.09
Recom2.00 SMA20-27.43% SMA50-35.16% SMA200-43.50% Volume176,461 Change1.22%
Oct-31-17Resumed Piper Jaffray Overweight $30
Oct-23-17Initiated ROTH Capital Neutral $15
Aug-10-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-17 08:57AM  Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher Zacks
Dec-11-17 02:30PM  5 Keys To Understanding Syros Pharma's ASH Presentation Benzinga -31.69%
01:12PM  Here's Why Syros Pharmaceuticals Got Crushed Today Motley Fool
12:13PM  Syros Pharmaceuticals Plummets in Premarket Trading Monday GuruFocus.com
09:28AM  Should You Be Content With Syros Pharmaceuticals Incs (SYRS) 71.5% Earnings Growth? Simply Wall St.
Dec-10-17 09:01AM  Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach Business Wire
09:01AM  Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Business Wire
Dec-07-17 08:01AM  Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium Business Wire
Dec-01-17 07:12AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : December 1, 2017 Capital Cube
Nov-27-17 07:50AM  Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma ACCESSWIRE
Nov-21-17 08:01AM  Syros to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 04:01PM  Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium Business Wire
08:01AM  Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer Business Wire
Nov-08-17 08:01AM  Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire -5.27%
Nov-02-17 01:08PM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : November 2, 2017 Capital Cube -16.79%
Nov-01-17 09:01AM  Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting Business Wire -11.69%
08:14AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017 Capital Cube
Oct-30-17 08:01AM  Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference Business Wire +6.55%
Oct-26-17 08:01AM  Syros Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress Business Wire -5.15%
Oct-20-17 04:01PM  Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress Business Wire
Oct-16-17 04:01PM  Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference Business Wire
Oct-05-17 08:01AM  Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML Business Wire
Sep-29-17 08:01AM  Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML Business Wire
Sep-11-17 07:01AM  Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RAR Agonist, in Genomically Defined AML and MDS Patients Business Wire -6.52%
Sep-05-17 08:01AM  Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference Business Wire
Sep-01-17 11:40AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017 Capital Cube
Aug-31-17 08:01AM  Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress Business Wire
Aug-21-17 09:20AM  Syros Pharma Wins Orphan Designation From FDA 24/7 Wall St.
08:01AM  Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML Business Wire
Aug-10-17 08:01AM  Syros Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference Business Wire -7.84%
Aug-09-17 04:05PM  Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
Jul-21-17 08:01AM  Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients Business Wire +5.29%
Jun-23-17 08:01AM  Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RAR Agonist, in Genomically Defined AML and MDS Patients Business Wire
Jun-19-17 08:01AM  Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting Business Wire +5.63%
Jun-15-17 03:25PM  ETFs with exposure to Syros Pharmaceuticals, Inc. : June 15, 2017 Capital Cube
Jun-13-17 04:01PM  Syros to Participate in JMP Securities Life Sciences Conference Business Wire
08:24AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : June 13, 2017 Capital Cube
Jun-12-17 08:01AM  Syros Appoints Srinivas Akkaraju to Its Board of Directors Business Wire +9.86%
May-29-17 08:20AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 29, 2017 Capital Cube
May-18-17 08:01AM  Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients Business Wire
May-15-17 04:31PM  Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones Business Wire
08:01AM  Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors Business Wire
May-11-17 07:36PM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : May 11, 2017 Capital Cube
May-09-17 08:52AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : May 9, 2017 Capital Cube
May-08-17 04:01PM  Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting Business Wire
08:01AM  Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
May-04-17 04:01PM  Syros Reveals Discovery of Novel Drug Targets for Triple Negative Breast Cancer Business Wire
May-01-17 08:01AM  Syros Participates in International Symposium to Support MDS Foundations Efforts to Raise Awareness of Novel Therapies in Development for MDS Business Wire
Apr-27-17 08:01AM  Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference Business Wire
Apr-26-17 04:05PM  Syros Closes $35 Million Private Financing Business Wire
Apr-21-17 08:01AM  Syros Announces $35 Million Private Placement Business Wire
Apr-18-17 08:01AM  Syros to Present on SY-1425, Its First-in-Class Selective RAR Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference Business Wire
Apr-10-17 08:01AM  Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors Business Wire
Apr-04-17 08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients Business Wire
08:01AM  Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RAR Agonist, for Genomically Defined AML and MDS Patients
Apr-03-17 08:01AM  Syros Presents New Preclinical Data at AACR Showing Anti-Tumor Activity of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Multiple Difficult-to-Treat Solid Tumors Business Wire
Mar-31-17 08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:31AM  Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
Mar-24-17 06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)? Zacks
06:33AM  Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
Mar-23-17 01:04PM  SYROS PHARMACEUTICALS, INC. Financials
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors Zacks
08:51AM  Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
Mar-21-17 09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Capital Cube -8.67%
09:55AM  Syros Pharmaceuticals, Inc. :SYRS-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 08:01AM  Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones Business Wire
07:02AM  SYROS PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-01-17 04:31PM  Syros to Present New Data on Lead Drug Candidates, SY-1425 and SY-1365, and CDK12/13 Inhibitor Program at Upcoming AACR Annual Meeting Business Wire
08:01AM  Syros Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Feb-27-17 08:01AM  Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference Business Wire
Feb-21-17 08:01AM  Syros Drug Discovery Research in Immuno-Oncology Highlighted at UCSD Moores Cancer Center Symposium Business Wire
Feb-09-17 04:01PM  Syros Announces Publication in Cell Highlighting Gene Control as Important and Rapidly Progressing Area of Research for Yielding New Medicines to Treat Cancer Business Wire
Feb-07-17 08:01AM  Syros Pharmaceuticals to Present at 2017 BIO CEO & Investor Conference Business Wire
Jan-30-17 08:39AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:01AM  Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors Business Wire
Jan-10-17 11:00AM  Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-09-17 09:02AM  SYROS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financia -9.03%
08:35AM  Syros Pharmaceuticals Announces 2017 Strategic Priorities and Goals Business Wire
Jan-06-17 07:35AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : January 6, 2017 -6.31%
Dec-27-16 11:30AM  Syros Pharmaceuticals, Inc. Value Analysis (NASDAQ:SYRS) : December 27, 2016 -10.11%
Dec-26-16 08:02AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : December 26, 2016
Dec-15-16 08:15PM  Is Syros Pharmaceuticals Inc (SYRS) A Good Stock To Buy? at Insider Monkey
12:20AM  A new name and new fund will ensure Cambridge's Flagship 'feels like a startup' at bizjournals.com
12:01AM  Flagship Ventures Evolves Name To Flagship Pioneering PR Newswire
Dec-10-16 08:30AM  Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects of its First-in-Class Selective RAR Agonist in Genomically Defined Subsets of Breast Cancer Business Wire
Dec-05-16 08:01AM  Syros Pharmaceuticals Presents Data at ASH Annual Meeting Further Supporting Clinical Potential of Its First-in-Class Selective RAR Agonist for Genomically Defined Subsets of AML and MDS Patients Business Wire
Nov-22-16 07:15AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 22, 2016
Nov-21-16 08:01AM  Syros Pharmaceuticals Announces Late-Breaking Presentation on SY-1425 at San Antonio Breast Cancer Symposium Business Wire +5.35%
Nov-18-16 08:51PM  [$$] Arch Venture Partners Raises $408M at The Wall Street Journal
Nov-14-16 08:23AM  Syros Pharmaceuticals reports 3Q loss
08:05AM  Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Business Wire
07:04AM  SYROS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 08:05AM  Syros Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire
Nov-03-16 09:01AM  Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RAR Agonist, at the ASH Annual Meeting Business Wire
Nov-02-16 08:27AM  Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : November 2, 2016 -11.21%
Oct-11-16 08:05AM  Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers Business Wire
Sep-26-16 08:05AM  Syros Announces Appointment of Gerald E. Quirk as Chief Legal Officer Business Wire
Sep-22-16 08:05AM  Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Business Wire
Sep-16-16 01:41PM  5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2 at Insider Monkey
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.